Berman Capital Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Berman Capital Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$1K	Buy	+18	New	+$1.04K	﹤0.01%	1993

Other funds holding ZNTL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Berman Capital Advisors's ZNTL Position: Q3 2021 in Review

Berman Capital Advisors opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q3 2021: 18 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #1993 among its holdings.

116 funds tracked by Wall St. Rank hold ZNTL as of Q3 2021.

Berman Capital Advisors held 18 shares of Zentalis Pharmaceuticals worth $1K as of Q3 2021.
Zentalis Pharmaceuticals was a new Berman Capital Advisors position in Q3 2021.
Zentalis Pharmaceuticals made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1993 holding.
116 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.